Proteasome Inhibitors Induce Apoptosis in Ex Vivo Cells of T-Cell Prolymphocytic Leukemia.

Authors: Gasparini, Vanessa Rebecca^1,2 (AUTHOR) vanessarebecca.gasparini@gmail.com, Rampazzo, Elisa^1,2 (AUTHOR) elisa.rampazzo.3@phd.unipd.it, Barilà, Gregorio³ (AUTHOR) gregorio.barila@aulss8.veneto.it, Buratin, Alessia⁴ (AUTHOR) aburatin@carrerasresearch.org, Buson, Elena^1,2 (AUTHOR) elena.buson.1@studenti.unipd.it, Calabretto, Giulia^1,2 (AUTHOR) giulia.calabretto@gmail.com, Vicenzetto, Cristina⁵ (AUTHOR) cristina.vicenzetto@aopd.veneto.it, Orsi, Silvia^4,6 (AUTHOR) silvia.orsi@phd.unipd.it, Tonini, Alessia¹ (AUTHOR) alessia.tonini@unipd.it, Teramo, Antonella^1,2 (AUTHOR) antonella.teramo@unipd.it, Trentin, Livio¹ (AUTHOR) livio.trentin@unipd.it, Facco, Monica^1,2 (AUTHOR) monica.facco@unipd.it, Semenzato, Gianpietro² (AUTHOR) g.semenzato@unipd.it, Bortoluzzi, Stefania^4,6 (AUTHOR) stefania.bortoluzzi@unipd.it, Zambello, Renato^1,2 (AUTHOR) r.zambello@unipd.it

Source: International Journal of Molecular Sciences. Dec2024, Vol. 25 Issue 24, p13573. 12p.

Subject Terms: *PROTEASOME inhibitors, *DRUG analysis, *DRUG repositioning, *ESSENTIAL drugs, *BORTEZOMIB

Proteasome inhibition suppresses the induction of lipocalin-2 upon systemic lipopolysaccharide challenge in mice.

Authors: Bae, Jin-Sil¹ (AUTHOR), Heo, Ji-Eun¹ (AUTHOR), Ryu, Kwon-Yul¹ (AUTHOR) kyryu@uos.ac.kr

Source: Molecular Brain. 10/3/2024, Vol. 17 Issue 1, p1-4. 4p.

Subject Terms: *LIPOCALIN-2, *PROTEASOME inhibitors, *INTRAPERITONEAL injections, *ASTROCYTES, *LIPOPOLYSACCHARIDES

Promising Therapeutic Strategies for Hematologic Malignancies: Innovations and Potential.

Authors: Lica, Jan Jakub¹ (AUTHOR) 24556@gumed.edu.pl, Pradhan, Bhaskar² (AUTHOR) bhaskar.pradhan@wum.edu.pl, Safi, Kawthar³ (AUTHOR), Jakóbkiewicz-Banecka, Joanna⁴ (AUTHOR) 24556@gumed.edu.pl, Hellmann, Andrzej⁵ (AUTHOR) andrzej.hellmann@gumed.edu.pl

Source: Molecules. Sep2024, Vol. 29 Issue 17, p4280. 40p.

Subject Terms: *HEMATOLOGIC malignancies, *PROTEASOME inhibitors, *SMALL molecules, *MEDICAL research, *PEPTIDES

Different Strategies to Overcome Resistance to Proteasome Inhibitors—A Summary 20 Years after Their Introduction.

Authors: Tyrna, Paweł¹ (AUTHOR) pawel.tyrna@gmail.com, Procyk, Grzegorz² (AUTHOR) grzegorz.procyk@wum.edu.pl, Szeleszczuk, Łukasz³ (AUTHOR) lukasz.szeleszczuk@wum.edu.pl, Młynarczuk-Biały, Izabela⁴ (AUTHOR) izabela.mlynarczuk-bialy@wum.edu.pl

Source: International Journal of Molecular Sciences. Aug2024, Vol. 25 Issue 16, p8949. 28p.

Subject Terms: *PROTEASOME inhibitors, *CELL cycle, *ANTINEOPLASTIC agents, *ENDOPLASMIC reticulum, *CELL survival, *PROTEOLYSIS

Integrated transcriptomics- and structure-based drug repositioning identifies drugs with proteasome inhibitor properties.

Authors: Larsson, Peter^1,2 peter.larsson.3@gu.se, De Rosa, Maria Cristina³, Righino, Benedetta³, Olsson, Maxim^1,2, Florea, Bogdan Iulius⁴, Forssell-Aronsson, Eva^2,5,6, Kovács, Anikó⁷, Karlsson, Per^1,8, Helou, Khalil^1,2, Parris, Toshima Z.^1,2

Source: Scientific Reports. 8/13/2024, Vol. 14 Issue 1, p1-18. 18p.

Subject Terms: *DRUG repositioning, *PROTEASOME inhibitors, *BORTEZOMIB, *DRUG side effects, *DOSAGE forms of drugs, *PHARMACOGENOMICS, *PROTEASOMES

The Proteasome Inhibitor Marizomib Evokes Endoplasmic Reticulum Stress and Promotes Apoptosis in Human Glioblastoma Cells.

Authors: Kusaczuk, Magdalena¹ (AUTHOR) mkusaczuk@wp.pl, Tyszka, Natalia¹ (AUTHOR), Krętowski, Rafał¹ (AUTHOR), Cechowska-Pasko, Marzanna¹ (AUTHOR) mkusaczuk@wp.pl

Source: Pharmaceuticals (14248247). Aug2024, Vol. 17 Issue 8, p1089. 15p.

Subject Terms: *CANCER cell physiology, *PROTEASOME inhibitors, *WESTERN immunoblotting, *ENDOPLASMIC reticulum, *CELL death

The Synergistic Effect of Reduced Graphene Oxide and Proteasome Inhibitor in the Induction of Apoptosis through Oxidative Stress in Breast Cancer Cell Lines.

Authors: Krętowski, Rafał¹ (AUTHOR) marzanna.cechowska-pasko@umb.edu.pl, Szynaka, Beata² (AUTHOR) beataszynaka@gmail.com, Jabłońska-Trypuć, Agata³ (AUTHOR) a.jablonska@pb.edu.pl, Kiełtyka-Dadasiewicz, Anna^4,5 (AUTHOR) anna.kieltyka-dadasiewicz@up.lublin.pl, Cechowska-Pasko, Marzanna¹ (AUTHOR)

Source: International Journal of Molecular Sciences. May2024, Vol. 25 Issue 10, p5436. 23p.

Subject Terms: *PROTEASOME inhibitors, *CANCER cells, *GRAPHENE oxide, *BREAST cancer, *CELL lines, *OXIDATIVE stress, *BREAST, *MAMMOGRAMS

The Proteasome Inhibitor CEP-18770 Induces Cell Death in Medulloblastoma.

Authors: Nath Varma, Swastina¹ (AUTHOR) t.varma@ucl.ac.uk, Ye, Shany² (AUTHOR) sy996@bath.ac.uk, Ferlin, Sara² (AUTHOR) slf49@bath.ac.uk, Comer, Charley² (AUTHOR) cc2736@bath.ac.uk, Cotton, Kian² (AUTHOR) kc691@bath.ac.uk, Niklison-Chirou, Maria Victoria^1,2 (AUTHOR) mvnc20@bath.ac.uk

Source: Pharmaceutics. May2024, Vol. 16 Issue 5, p672. 15p.

Subject Terms: *PROTEASOME inhibitors, *MEDULLOBLASTOMA, *ANTINEOPLASTIC agents, *CELL death, *CISPLATIN, *MULTIPLE myeloma

Effect of proteasome inhibitors on canine lymphoma cell response to CHOP chemotherapy in vitro.

Authors: Prevedel, Nicholas E.¹ (AUTHOR), Mee, Miles W.¹ (AUTHOR), Wood, Geoffrey A.² (AUTHOR), Coomber, Brenda L.¹ (AUTHOR) bcoomber@uoguelph.ca

Source: Veterinary & Comparative Oncology. Mar2024, Vol. 22 Issue 1, p96-105. 10p.

Subject Terms: *PROTEASOME inhibitors, *CANCER chemotherapy, *LYMPHOMAS, *BORTEZOMIB, *GENE expression, *RITUXIMAB, *PROTEASOMES

Autophagy and oxidative stress modulation mediate Bortezomib resistance in prostate cancer.

Authors: Zafeiropoulou, Kalliopi^1,2 (AUTHOR), Kalampounias, Georgios¹ (AUTHOR), Alexis, Spyridon² (AUTHOR), Anastasopoulos, Daniil¹ (AUTHOR), Symeonidis, Argiris² (AUTHOR), Katsoris, Panagiotis¹ (AUTHOR) katsopan@upatras.gr

Source: PLoS ONE. 2/27/2024, Vol. 19 Issue 2, p1-23. 23p.

Subject Terms: *BORTEZOMIB, *PROTEASOME inhibitors, *WALDENSTROM'S macroglobulinemia, *PROSTATE cancer, *OXIDATIVE stress, *MANTLE cell lymphoma, *AUTOPHAGY

Interplay between proteasome inhibitors and NF-κB pathway in leukemia and lymphoma: a comprehensive review on challenges ahead of proteasome inhibitors.

Authors: Pakjoo, Mahdi^1,2 (AUTHOR), Ahmadi, Seyed Esmaeil³ (AUTHOR), Zahedi, Mohammad⁴ (AUTHOR), Jaafari, Niloofar³ (AUTHOR), Khademi, Reyhane⁵ (AUTHOR), Amini, Ali³ (AUTHOR) aminia2010@gmail.com, Safa, Majid³ (AUTHOR) majidsafa@gmail.com

Source: Cell Communication & Signaling. 2/8/2024, Vol. 22 Issue 1, p1-28. 28p.

Subject Terms: *PROTEASOME inhibitors, *TUMOR suppressor proteins, *SCIENTIFIC literature, *LEUKEMIA, *HEMATOLOGIC malignancies

The effective multiplicity of infection for HCMV depends on the activity of the cellular 20S proteasome.

Authors: Cataldo, Katie M.¹, Roche, Kathryn L.², Monti, Christopher E.^1,2, Dash, Ranjan K.^3,4, Murphy, Eain A.⁵, Terhune, Scott S.^1,3 sterhune@mcw.edu

Source: Journal of Virology. Jan2025, Vol. 99 Issue 1, p1-19. 19p.

Subject Terms: *CYCLIN-dependent kinase inhibitors, *PROTEASOME inhibitors, *HUMAN cytomegalovirus, *VIRAL proteins, *CELL populations

Combination of bortezomib and venetoclax targets the pro-survival function of LMP-1 and EBNA-3C of Epstein-Barr virus in spontaneous lymphoblastoid cell lines.

Authors: Tam, Kam Pui¹, Xie, Jia¹, Au-Yeung, Rex Kwok Him², rex.auyeung@hku.hk, Chiang, Alan K. S.¹, chiangak@hku.hk

Source: PLoS Pathogens; 9/26/2024, Vol. 20 Issue 9, p1-24, 24p

Reduction of HLA donor specific antibodies in heart transplant patients treated with proteasome inhibitors for antibody mediated rejection.

Authors: Horn, Edward T.¹ (AUTHOR) horne@upmc.edu, Xu, Qingyong² (AUTHOR), Dibridge, Julie N.³ (AUTHOR), Huston, Jessica H.⁴ (AUTHOR), Hickey, Gavin W.⁴ (AUTHOR), Kaczorowski, David J.⁵ (AUTHOR), Keebler, Mary E.⁴ (AUTHOR), Zeevi, Adriana² (AUTHOR)

Source: Clinical Transplantation. Dec2023, Vol. 37 Issue 12, p1-9. 9p.

Subject Terms: *HEART transplant recipients, *PROTEASOME inhibitors, *BORTEZOMIB, *GRAFT rejection, *HEART transplantation, *IMMUNOGLOBULINS

New Insights for Polyphenolic Compounds as Naturally Inspired Proteasome Inhibitors.

Authors: Marchese, Emanuela¹ (AUTHOR) e.marchese@unicz.it, Gallo Cantafio, Maria Eugenia² (AUTHOR) mariaeugenia.gallocantafio@unicz.it, Ambrosio, Francesca Alessandra² (AUTHOR) ambrosio@unicz.it, Torcasio, Roberta² (AUTHOR) ilenia.valentino30@gmail.com, Valentino, Ilenia² (AUTHOR) trapasso@unicz.it, Trapasso, Francesco² (AUTHOR) viglietto@unicz.it, Viglietto, Giuseppe² (AUTHOR), Alcaro, Stefano^1,3,4 (AUTHOR) alcaro@unicz.it, Costa, Giosuè^1,3 (AUTHOR) gcosta@unicz.it, Amodio, Nicola² (AUTHOR) ambrosio@unicz.it

Source: Pharmaceuticals (14248247). Dec2023, Vol. 16 Issue 12, p1712. 13p.

Subject Terms: *PROTEASOME inhibitors, *MULTIPLE myeloma, *PLANT polyphenols, *ANTINEOPLASTIC agents, *PROTEASOMES, *NATURAL products, *POLYPHENOLS

Company/Entity: UNITED States. Food & Drug Administration

Clarithromycin overcomes stromal cell-mediated drug resistance against proteasome inhibitors in myeloma cells via autophagy flux blockage leading to high NOXA expression.

Authors: Moriya, Shota¹ (AUTHOR) moriya@tokyo-med.ac.jp, Kazama, Hiromi¹ (AUTHOR), Hino, Hirotsugu^1,2 (AUTHOR), Takano, Naoharu¹ (AUTHOR), Hiramoto, Masaki¹ (AUTHOR), Aizawa, Shin² (AUTHOR), Miyazawa, Keisuke¹ (AUTHOR) moriya@tokyo-med.ac.jp

Source: PLoS ONE. 12/1/2023, Vol. 18 Issue 12, p1-21. 21p.

Subject Terms: *MESENCHYMAL stem cells, *PROTEASOME inhibitors, *DRUG resistance, *CELL adhesion, *AUTOPHAGY, *CLARITHROMYCIN

IMiD-Free Interval and IMiDs Sequence: Which Strategy Is Better Suited for Lenalidomide-Refractory Myeloma?

Authors: Suzuki, Kazuhito¹ (AUTHOR) kaz-suzuki@jikei.ac.jp, Yano, Shingo¹ (AUTHOR)

Source: Life (2075-1729). Nov2023, Vol. 13 Issue 11, p2229. 15p.

Subject Terms: *MULTIPLE myeloma, *PROTEASOME inhibitors, *DRUG therapy, *MONOCLONAL antibodies, *SALVAGE therapy

Proteasome Inhibitors against Glioblastoma—Overview of Molecular Mechanisms of Cytotoxicity, Progress in Clinical Trials, and Perspective for Use in Personalized Medicine.

Authors: Gozdz, Agata¹ (AUTHOR) agozdz@wum.edu.pl

Source: Current Oncology. Nov2023, Vol. 30 Issue 11, p9676-9688. 13p.

Subject Terms: *METHYLGUANINE, *PROTEASOME inhibitors, *BORTEZOMIB, *CYTOTOXINS, *INDIVIDUALIZED medicine, *CLINICAL trials, *GLIOBLASTOMA multiforme

Immunomodulatory Effect of Proteasome Inhibitors via the Induction of Immunogenic Cell Death in Myeloma Cells.

Authors: Matsushita, Maiko¹ (AUTHOR) matsushita-mk@pha.keio.ac.jp, Kashiwazaki, Sho¹ (AUTHOR), Kamiko, Satoshi¹ (AUTHOR), Kobori, Michio¹ (AUTHOR), Osada, Makoto² (AUTHOR) makoosd.0221@gmail.com, Kunieda, Hisako² (AUTHOR), Hirao, Maki³ (AUTHOR), Ichikawa, Daiju¹ (AUTHOR), Hattori, Yutaka^1,2 (AUTHOR)

Source: Pharmaceuticals (14248247). Oct2023, Vol. 16 Issue 10, p1367. 15p.

Subject Terms: *PROTEASOME inhibitors, *T cells, *CELL death, *UNFOLDED protein response, *CHIMERIC antigen receptors, *CANCER cells, *ANTINEOPLASTIC agents, *T cell receptors

Discovery of a Novel Ubenimex Derivative as a First-in-Class Dual CD13/Proteasome Inhibitor for the Treatment of Cancer.

Authors: Zhang, Jian¹ (AUTHOR) zhangjian_3323@163.com, Sun, Simin² (AUTHOR) lixiaoyang@ouc.edu.cn, Liu, Jinyu² (AUTHOR), Zhang, Liang² (AUTHOR), Guo, Di¹ (AUTHOR), Zhang, Naixin³ (AUTHOR), Zhao, Jun⁴ (AUTHOR), Kong, Dexin³ (AUTHOR), Xu, Tongqiang⁴ (AUTHOR), Wang, Xuejian¹ (AUTHOR), Xu, Wenfang^4,5 (AUTHOR), Li, Xiaoyang^2,4,5 (AUTHOR), Jiang, Yuqi^2,4 (AUTHOR) jiangyuqi@ouc.edu.cn

Source: Molecules. Sep2023, Vol. 28 Issue 17, p6343. 17p.

Subject Terms: *PROTEASOME inhibitors, *CANCER treatment, *ANTINEOPLASTIC agents, *CANCER chemotherapy, *MULTIPLE myeloma, *ADJUVANT chemotherapy